Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor monotherapy in JAK inhibitor-naive myelofibrosis with moderate thrombocytopenia
NL-OMON59091Phase 2Active, not recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in myelofibrosis (MF), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Proportion of patients with SVR35 at Week 24. Started Aug 2024; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON59091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59091.